• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Lab Anal . Serological chemiluminescence immunoassay for the diagnosis of SARS-CoV-2 infection

tetano

Editor, Senior Moderator
J Clin Lab Anal


. 2020 Jul 16;e23466.
doi: 10.1002/jcla.23466. Online ahead of print.
Serological chemiluminescence immunoassay for the diagnosis of SARS-CoV-2 infection


Shao Lijia[SUP] 1 [/SUP], Shen Lihong[SUP] 1 [/SUP], Wang Huabin[SUP] 2 [/SUP], Xu Xiaoping[SUP] 1 [/SUP], Lu Xiaodong[SUP] 1 [/SUP], Zhu Yixuan[SUP] 1 [/SUP], He Pin[SUP] 1 [/SUP], Xu Yina[SUP] 1 [/SUP], Shan Xiaoyun[SUP] 1 [/SUP], Wu Junqi[SUP] 1 [/SUP]



Affiliations

Abstract

Objective: Dynamic monitoring of the concentration variation of IgM and IgG in patients with SARS-CoV-2 infections and exploring their diagnostic value for coronavirus disease-19 (COVID-19).
Methods: A total of 15 patients with SARS-CoV-2 infection were enrolled as the COVID-19 group, and 50 patients were enrolled as the control group. The concentrations of SARS-CoV-2-specific antibodies (IgM and IgG) were detected by a chemiluminescence immunoassay (CLIA).
Results: According to the cutoff value recommended by the manufacturer (cutoff = 10 AU/mL), the sensitivity, specificity, Youden index (YI), positive predictive value (PPV), and negative predictive value (NPV) of IgM were 60%, 100%, 60%, 100%, and 89.29%, respectively; and 86.67%, 100%, 86.67%, 100%, and 96.15%, respectively, for IgG. We reassessed the cutoff value of IgM. When the cutoff value for SARS-CoV-2 IgM was 1.83 AU/mL, the sensitivity, specificity, YI, PPV, and NPV were 93.33%, 98%, 91.33%, 93.33%, and 98%, respectively. During dynamic monitoring of the concentrations of IgM and IgG in COVID-19 patients, we found the shortest times before a patient became IgM and IgG seropositive after symptom onset were 1.5 and 2 days, respectively. The longest times were 7 and 8 days, respectively. The positive rates of SARS-CoV-2 IgM and IgG both reached 100% in 8-14 days after symptom onset.
Conclusion: The IgM cutoff value of 1.83 AU/mL for the diagnosis of COVID-19 was much better than the cutoff suggested by the manufacturer. SARS-CoV-2 infection can be ruled out if antibodies against SARS-CoV-2 are still undetectable 14 days after symptom onset.

Keywords: COVID-19; SARS-CoV-2; antibody; diagnostic value.
 
Back
Top Bottom